Powles T, et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). ASCO-GU 2019, abstract 545.
Tijdelijke vergoeding trastuzumab deruxtecan (Enhertu)
apr 2024 | Borstkanker